A single administration of gemtuzumab ozogamicin for molecular relapse of acute promyelocytic leukemia.
Schwarz
Jirí
J
Marková
Jana
J
Peková
Sona
S
Trnková
Zuzana
Z
Sponerová
Dana
D
Cetkovský
Petr
P
D000328:Adult; D000617:Aminoglycosides / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000079982:Gemtuzumab; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*; D007958:Leukocyte Count; D008297:Male; D018365:Neoplasm, Residual / Q000276:immunology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000922:Immunotoxins; D014212:Tretinoin; D000079982:Gemtuzumab